Exhibit 99.1
Earnings Release FY19 Q3
Investor Contacts
Media Contact
Gerry Gould, VP-Investor Relations
Carla Burigatto, VP-Communications
(781) 356-9402
(781) 348-7263
Olga Vlasova, Sr. Mgr.-Investor Relations
(781) 356-9763
Haemonetics Reports 3rd Quarter and Year-to-Date Fiscal 2019 Results; Raises Cash Flow Guidance and Reaffirms Other Fiscal 2019 Guidance

Braintree, MA, February 5, 2019
- Haemonetics Corporation (NYSE: HAE) reported results for its third quarter and year-to-date ("YTD") fiscal 2019, which ended December 29, 2018:    
3rd Quarter 2019
YTD 2019
Revenue, increase
$247 million, +5.7%
$718 million, +7.1%
Revenue increase, constant currency
Net income per diluted share
Adjusted net income per diluted share
Cash flow from operating activities
$58 million
$139 million
Free cash flow before restructuring & turnaround
$37 million
$58 million

Chris Simon, Haemonetics’ CEO, stated: “Our third quarter performance met our expectations and reinforces that our strategy is working. Our Plasma and Hospital launches are propelling us forward while our Complexity Reduction Initiative is improving profitability and freeing up resources needed for investments. We are confident that our value drivers will continue to strengthen Haemonetics’ growth trajectory.”


Third quarter fiscal 2019 revenue of $247.4 million was up 5.7% and YTD fiscal 2019 revenue of $718.3 million was up 7.1%, compared with the same periods of fiscal 2018. Business unit revenue and revenue growth rates versus prior fiscal year periods were as follows ($ million):
3rd Quarter 2019
YTD 2019
$ 48.4
Blood Center
$ 67.2
( 9.5%)
( 5.5%)

Gross margin was 44.9% in the third quarter of fiscal 2019, down 270 basis points as compared with the same quarter of the prior year, as $4.8 million of accelerated device depreciation was included in the third quarter of the current fiscal year.


The following information was filed by Haemonetics Corp (HAE) on Tuesday, February 5, 2019 as an 8K 2.02 statement, which is an earnings press release pertaining to results of operations and financial condition. It may be helpful to assess the quality of management by comparing the information in the press release to the information in the accompanying 10-Q Quarterly Report statement of earnings and operation as management may choose to highlight particular information in the press release.

View differences made from one quarter to another to evaluate Haemonetics Corp's financial trajectory

Compare SEC Filings Year-over-Year (YoY) and Quarter-over-Quarter (QoQ)
Sample 10-K Year-over-Year (YoY) Comparison

Compare this 10-Q Quarterly Report to its predecessor by reading our highlights to see what text and tables were  removed  ,   added    and   changed   by Haemonetics Corp.


Never Miss A New SEC Filing Again

Real-Time SEC Filing Notifications
Screenshot taken from Gmail for a new 10-K Annual Report Member Feature

Receive an e-mail as soon as a company files an Annual Report, Quarterly Report or has new 8-K corporate news.


We Highlighted This SEC Filing For You

SEC Filing Sentiment Analysis - Bullish, Bearish, Neutral
Screenshot taken from Wynn's 2018 10-K Annual Report Member Feature

Read positive and negative remarks made by management in their entirety without having to find them in a 10-K/Q.


Widen Your SEC Filing Reading Experience

Increased Reading Area for SEC Filings
Screenshot taken from Adobe Inc.'s 10-Q Quarterly Report Member Feature

Remove data columns and navigations in order to see much more filing content and tables in one view


Uncover Actionable Information Inside SEC Filings

SEC Filing Disclosures
Screenshot taken from Lumber Liquidators 10-K Annual Report Member Feature

Read both hidden opportunities and early signs of potential problems without having to find them in a 10-K/Q


Log in with your credentials


Forgot your details?

Create Account